Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- WuXi BiologicsWuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG LeadershipForbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China...
- MESSAGE DU CEO DE TME PHARMATME Pharma informe ses actionnaires des négociations finales pour NOX-A12, de sa rigueur financière, de la faible dilution et du marché biotech.
- TME PHARMA CEO MESSAGETME Pharma updates shareholders on final NOX-A12 license talks, capital discipline, minimal dilution, and capturing positive biotech market momentum.
- THE ROSEN LAW FIRM, P. A.ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYRosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class...
- Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineCapricor Therapeutics (CAPR) Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMPomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONPomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- Royalty Pharma plc NEW YORK andRoyalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration ProgramRoyalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United’s Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
- Blood Cancer United® formerly The Leukemia & Lymphoma SocietyBlood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration ProgramDonation marks a new phase for Blood Cancer United's venture philanthropy program, with returns reinvested to support future therapies — Blood Cancer United and Royalty Pharma today announced a $7.5 million donation from Royalty...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Urges Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Before the Securities Class Action Deadline on September 28, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may...
- ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
- ENvue Medical, Inc.ENvue Medical Provides Nasdaq Listing UpdateENvue Medical, Inc. (Nasdaq: FEED) (“ENvue” or the “Company”), a medical technology company focused on innovative solutions for enteral feeding and therapeutic ultrasound, today announced that it has received a decision from the Nasdaq Hearings Panel (the “Panel”) denying the Company’s request for continued listing on The Nasdaq Capital Market. As a result, trading of the Company’s common stock will be suspended and will begin trading on the OTC Markets under the same stock symbol, ‘FEED’, on September 16, 2026.